CCR3 Modulation for Aging-Associated Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging leads to structural and neurophysiological changes in the nervous system, resulting in cognitive decline and increased susceptibility to degenerative disorders, with synapse loss being a common pathological event in both normal aging and neurodegenerative diseases like Alzheimer's, posing a significant risk for cognitive impairments as the population ages.
Innovation Solution
Modulating CCR3, specifically through the eotaxin-1/CCR3 interaction, to treat aging-associated impairments, including cognitive impairments, by reducing active systemic eotaxin-1 levels or inhibiting its activity to mitigate the negative effects on neurogenesis and synaptic plasticity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If aging progresses naturally, then lifespan increases, but cognitive function deteriorates and susceptibility to neurodegenerative disorders increases
Solution Approach 1:
The patent applies preliminary anti-action by administering CCR3 modulators before significant cognitive decline occurs. The treatment aims to prevent or delay the onset of neurodegenerative changes by modulating CCR3 activity in advance, thereby counteracting the inevitable cognitive deterioration that accompanies aging and extending the period of healthy cognitive function throughout extended lifespan.
2Reliability
If synapse loss occurs during aging, then neuronal death is avoided, but cognitive impairment still results
Solution Approach 1:
The patent converts the harmful effect of synapse loss into a beneficial treatment target. By identifying CCR3 as a key mediator in synapse loss pathways, the invention uses CCR3 modulators to intervene in this degenerative process. The treatment transforms the understanding of synapse loss from an unavoidable age-related harm into a treatable condition, thereby preserving cognitive function while accepting that some synapse loss occurs with aging.
3Reliability
If CCR3 is modulated to treat aging-associated impairments, then cognitive function is improved, but treatment complexity increases
Solution Approach 1:
The patent uses CCR3 as an intermediary target to achieve cognitive protection. Rather than directly protecting neurons or synapses, the treatment modulates CCR3 activity, which then exerts downstream effects on neuroinflammation, synaptic plasticity, and neuronal survival. This intermediary approach simplifies the treatment mechanism to a single molecular target while achieving multiple protective effects, reducing overall treatment complexity despite the multifaceted nature of aging-associated cognitive decline.
Data Source
AI summary
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.